Browsing Tag
Johnson & Johnson
103 posts
Why are activist hedge funds circling Kenvue and what does Sachem Head’s entry signal for investors?
Activist hedge funds including Sachem Head are circling Kenvue. Find out what’s driving the pressure and what it means for investors.
Johnson & Johnson seeks EMA approval to expand AKEEGA use for HRR-altered prostate cancer patients
Johnson & Johnson files for EMA approval to extend AKEEGA use in high-risk prostate cancer. Find out how this combo may redefine standard of care.
Why are Johnson & Johnson’s ACUVUE OASYS MAX 1‑Day lenses gaining attention from investors and eye care professionals?
Will Johnson & Johnson’s new dual-correction lens reshape the global eye care market? Discover what’s next in the presbyopia and astigmatism segment.
Johnson & Johnson launches world’s first daily disposable lens for astigmatism and presbyopia
Johnson & Johnson unveils world’s first daily disposable lens for astigmatism and presbyopia. Discover how this innovation could shift global eye care.
Johnson & Johnson posts sustained superiority for IMAAVY in gMG vs rival FcRn blockers in 24-week indirect comparison
New 24-week comparison shows Johnson & Johnson’s IMAAVY outperforms other FcRn blockers in gMG control—see what this means for patients and investors.
How Protagonist Therapeutics is building a multi‑indication macrocyclic peptide portfolio with icotrokinra and beyond
Protagonist Therapeutics is building a multi-indication oral biologics platform with icotrokinra and rusfertide. Learn how its macrocyclic peptides are redefining therapy.
Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma
DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis.
Leyden Labs secures €20m from European Investment Bank: Could this reshape Europe’s pandemic response strategy?
Leyden Labs secures €20M EIB funding under HERA Invest to develop intranasal antibody sprays targeting pandemic flu and respiratory threats.
Halozyme Therapeutics stock rises 6.27% after beating Q1 expectations, raising 2025 outlook
Halozyme Therapeutics stock rose as Q1 earnings beat expectations and 2025 guidance improved. See how ENHANZE® drives royalty growth and future prospects.
China just blinked: U.S. drugs spared from tariff hike—Here’s what that means
China exempts select U.S. pharmaceuticals from new 125% tariffs; firms like CSL and Merck assess supply chain resilience.